• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

显微镜下非根治性食管切除术治疗食管和食管胃交界部癌的结果:全国性队列研究。

Outcome of microscopically non-radical oesophagectomy for oesophageal and oesophagogastric junctional cancer: nationwide cohort study.

机构信息

Department of Surgery, Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Department of Surgery, Västervik Hospital, Västervik, Sweden.

出版信息

BJS Open. 2021 May 7;5(3). doi: 10.1093/bjsopen/zrab038.

DOI:10.1093/bjsopen/zrab038
PMID:33972990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8110895/
Abstract

BACKGROUND

Microscopically non-radical (R1) oesophageal cancer resection has been associated with worse survival. The aim of this study was to identify risk factors for R1 resection and to investigate how this affects long-term survival.

METHODS

The Swedish National Register for Oesophageal and Gastric Cancer was used to identify all patients who underwent oesophageal cancer resection with curative intent between 2006 and 2017. Risk factors for R1 resection were assessed by multivariable logistic regression analysis, and factors predicting 5-year survival identified by multivariable Cox regression.

RESULTS

The study included 1460 patients. Surgical margins were involved microscopically in 142 patients (9.7 per cent). The circumferential resection margin was involved in 114 (7.8 per cent), the proximal margin in 53 (3.6 per cent), and the distal margin in 29 (2.0 per cent). In 30 specimens (2.1 per cent), two or all three margins were involved. Independent risk factors for R1 resection were male sex, low BMI, absence of neoadjuvant treatments, and clinical T4 disease. The 5-year survival rate for the entire cohort was 42.2 per cent, but only 18.0 per cent for those who had an R1 resection. Independent risk factors for death within 5 years of resection were male sex, age above 60 years, normal BMI, ASA fitness grade III, intermediate-level education, R1 resection (hazard ratio 1.80, 95 per cent c.i. 1.40 to 2.32), clinical T3 disease, and clinical lymph node metastasis.

CONCLUSION

R1 resection is common and predicts poor 5-year survival. Absence of neoadjuvant treatment is a risk factor for R1 resection.

摘要

背景

显微镜下非根治性(R1)食管切除术与生存率较差相关。本研究旨在确定 R1 切除术的危险因素,并研究其如何影响长期生存。

方法

使用瑞典食管癌和胃癌登记处,确定 2006 年至 2017 年间所有接受根治性食管切除术的患者。通过多变量逻辑回归分析评估 R1 切除术的危险因素,并通过多变量 Cox 回归确定预测 5 年生存率的因素。

结果

研究纳入 1460 例患者。142 例(9.7%)患者的手术切缘存在显微镜下累及。114 例(7.8%)累及环周切缘,53 例(3.6%)累及近端切缘,29 例(2.0%)累及远端切缘,30 例(2.1%)累及两个或所有三个切缘。R1 切除术的独立危险因素为男性、低 BMI、无新辅助治疗和临床 T4 期疾病。全队列的 5 年生存率为 42.2%,但 R1 切除术患者仅为 18.0%。切除后 5 年内死亡的独立危险因素为男性、年龄大于 60 岁、BMI 正常、ASA 体能状态 III 级、中等教育程度、R1 切除术(风险比 1.80,95%置信区间 1.40 至 2.32)、临床 T3 期疾病和临床淋巴结转移。

结论

R1 切除术常见且预测 5 年生存率差。无新辅助治疗是 R1 切除术的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b0/8110895/30249bd27114/zrab038f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b0/8110895/30249bd27114/zrab038f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/25b0/8110895/30249bd27114/zrab038f1.jpg

相似文献

1
Outcome of microscopically non-radical oesophagectomy for oesophageal and oesophagogastric junctional cancer: nationwide cohort study.显微镜下非根治性食管切除术治疗食管和食管胃交界部癌的结果:全国性队列研究。
BJS Open. 2021 May 7;5(3). doi: 10.1093/bjsopen/zrab038.
2
Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction.食管胃交界部 Siewert Ⅱ型和Ⅲ型腺癌经食管裂孔胃切除术的近端切缘长度。
Br J Surg. 2013 Jul;100(8):1050-4. doi: 10.1002/bjs.9170.
3
Geographical differences in cancer treatment and survival for patients with oesophageal and gastro-oesophageal junctional cancers.癌症患者的癌症治疗和生存的地理差异:食管和胃食管交界处癌症。
Br J Surg. 2020 Oct;107(11):1500-1509. doi: 10.1002/bjs.11671. Epub 2020 Jun 2.
4
Oesophagectomy rates and post-resection outcomes in patients with cancer of the oesophagus and gastro-oesophageal junction: a population-based study using linked health administrative linked data.食管和胃食管交界处癌症患者的食管切除术率和术后结果:使用基于人群的健康管理关联数据进行的研究。
BMC Health Serv Res. 2012 Nov 8;12:384. doi: 10.1186/1472-6963-12-384.
5
Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophagogastric junction.食管及食管胃交界腺癌的食管切除术结果
ANZ J Surg. 2005 Jul;75(7):513-9. doi: 10.1111/j.1445-2197.2005.03433.x.
6
Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy.新辅助治疗和食管切除术后淋巴结外侵犯的预后影响。
Br J Surg. 2016 Nov;103(12):1658-1664. doi: 10.1002/bjs.10226. Epub 2016 Oct 3.
7
Gastrectomy compared to oesophagectomy for Siewert II and III gastro-oesophageal junctional cancer in relation to resection margins, lymphadenectomy and survival.胃切除术与食管切除术治疗 Siewert II 和 III 型胃食管交界处癌的比较,涉及切缘、淋巴结清扫和生存。
Sci Rep. 2017 Dec 19;7(1):17783. doi: 10.1038/s41598-017-18005-6.
8
Impact of age and co-morbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer.年龄和合并症对食管和胃癌患者手术切除率和生存率的影响。
Br J Surg. 2012 Dec;99(12):1693-700. doi: 10.1002/bjs.8952.
9
Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.新辅助放化疗后食管癌患者环周切缘的预后价值及其定义
Dis Esophagus. 2018 Feb 1;31(2). doi: 10.1093/dote/dox117.
10
Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.腺癌患者食管切除术后切缘阳性的辅助治疗。
Br J Surg. 2020 Dec;107(13):1801-1810. doi: 10.1002/bjs.11864. Epub 2020 Sep 29.

引用本文的文献

1
Incidence and Predictors of Textbook Outcome after Minimally Invasive Esophagectomy for Cancer: A Two-Center Study.微创食管癌切除术后癌症的教科书式结局的发生率及预测因素:一项双中心研究。
Cancers (Basel). 2024 Mar 9;16(6):1109. doi: 10.3390/cancers16061109.

本文引用的文献

1
Complications and survival after hybrid and fully minimally invasive oesophagectomy.杂交手术和完全微创食管切除术后的并发症及生存率
BJS Open. 2021 Jan 8;5(1). doi: 10.1093/bjsopen/zraa033.
2
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗(FLOT4):一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
3
Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
食管癌腺癌的新辅助化疗或放化疗
J Surg Oncol. 2018 Jun;117(8):1687-1696. doi: 10.1002/jso.25089. Epub 2018 May 28.
4
Prognostic value of the circumferential resection margin and its definitions in esophageal cancer patients after neoadjuvant chemoradiotherapy.新辅助放化疗后食管癌患者环周切缘的预后价值及其定义
Dis Esophagus. 2018 Feb 1;31(2). doi: 10.1093/dote/dox117.
5
Modifiable factors and esophageal cancer: a systematic review of published meta-analyses.可改变因素与食管癌:已发表荟萃分析的系统评价。
J Gastroenterol. 2018 Jan;53(1):37-51. doi: 10.1007/s00535-017-1375-5. Epub 2017 Aug 18.
6
Does the Margin Matter in Esophageal Cancer.食管癌的切缘重要吗?
Dig Surg. 2018;35(3):196-203. doi: 10.1159/000478669. Epub 2017 Jul 12.
7
Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.食管癌和食管胃交界癌——美国癌症联合委员会第八版癌症分期手册的重大变化。
CA Cancer J Clin. 2017 Jul 8;67(4):304-317. doi: 10.3322/caac.21399. Epub 2017 May 26.
8
Worldwide Esophageal Cancer Collaboration: clinical staging data.全球食管癌协作组:临床分期数据。
Dis Esophagus. 2016 Oct;29(7):707-714. doi: 10.1111/dote.12493.
9
Validation of data quality in the Swedish National Register for Oesophageal and Gastric Cancer.瑞典食管和胃癌国家登记处数据质量的验证。
Br J Surg. 2016 Sep;103(10):1326-35. doi: 10.1002/bjs.10234. Epub 2016 Jul 28.
10
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.一项关于新辅助化疗与新辅助放化疗治疗食管癌或胃食管交界癌的随机临床试验。
Ann Oncol. 2016 Apr;27(4):660-7. doi: 10.1093/annonc/mdw010. Epub 2016 Jan 17.